Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Recruiting

Phase 2

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung CancerTemozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Sponsor:

Dwight Owen

Code:

NCT04919382

Conditions

Extensive Stage Lung Small Cell Carcinoma

Metastatic Lung Small Cell Carcinoma

Recurrent Lung Small Cell Carcinoma

Stage IV Lung Cancer AJCC v8

Stage IVA Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Dwight Owen on 2024-09-27.